Storia in 3 fonti

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat - Arrowhead Pharma (NASDAQ:ARWR)

The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreatitis reductions.

Raccontata da

biopharmadive.com

endpoints.news

benzinga.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo9 h fa

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat - Arrowhead Pharma (NASDAQ:ARWR)

The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreatitis reductions.

originale

biopharmadive.com1 g fa

Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.

Leggi questa versione → originale

endpoints.news12 h fa

Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease

Arrowhead's Redemplo cut triglycerides 79%-81% in two Phase 3 trials for sHTG, boosting the company's shares by about 25%.

Leggi questa versione → originale

Timeline cronologica

mercoledì 22 luglio 2026·biopharmadive.com
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
mercoledì 22 luglio 2026·endpoints.news
Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease
Arrowhead's Redemplo cut triglycerides 79%-81% in two Phase 3 trials for sHTG, boosting the company's shares by about 25%.
mercoledì 22 luglio 2026·benzinga.com
Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat - Arrowhead Pharma (NASDAQ:ARWR)
The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreatitis reductions.